Slide 1: Results Presentation for the Full Year Ended 30 June 2022
For personal use only For immediate release 17 August 2022 RESULTS PRESENTATION FOR THE FULL YEAR ENDED 30 JUNE 2022 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and C
Slide 2: CSL Limited 2022 Full Year Results
For personal use only CSL Limited 2022 Full Year Results 17 August 2022 Paul Perreault Joy Linton CEO and Managing CFO Director
Slide 3: Important Notice and Disclaimer
For personal use only IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 004 089 936) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does no
Slide 4: CEO Overview
For personal use only CEO Overview Paul Perreault CEO & Managing Director 3
Slide 5: FY22 Performance
FY22 Performance1 Revenue up 3% with net profit after tax down 6% For personal use only CSL Behring CSL Seqirus Performance • IDELVION® +20% • Seasonal influenza vaccines +16% in line with expectations • KCENTRA® +18% − FLUAD ® +41% As expected Ig and Albumin sales have • HAEGARDA® +5% − US sales >$
Slide 6: CSL Behring
CSL Behring Revenue up 2%1 For personal use only Revenue Change1 Therapy $m % Revenue By Region1 Immunoglobulins 4,024 (3%) IVIG 2,511 (5%) SCIG 1,513 (0%) 1% (5%) Albumin 1,072 (1%) EU / UK 24% Haemophilia 1,166 8% Recombinants 759 16% North America US$8.6B 49% 2% Plasma 407 (4%) Asia Specialty 1,7
Slide 7: Immunoglobulins
Immunoglobulins1 Sales down 3% For personal use only Supply constrained environment curtailed growth • Improved second half performance reflects growth in plasma collected HIZENTRA® • Continued steady uptake for CIDP – Enhanced neurologists confidence driven by independent guideline support2 Market
Slide 8: Albumin
Albumin1 Sales down 1% For personal use only China Other markets • Maintained market leadership • EU and ROW declined due to the position with sales up 10% localisation of supply • Expanded hospital share with • Decline in US as supply brand differentiation and effective constraints continued from H
Slide 9: Haemophilia
Haemophilia1 Sales up 8% For personal use only Recombinant Coags +16% • IDELVION® − Market leader and most prescribed product in the prophylactic segment − Compelling clinical profile drives patient demand and market share − Extension study enhances long term efficacy and safety profile − Continued
Slide 10: Specialty Products
Specialty Products1 Sales up 3% For personal use only FY22 Sales HAE Hospital Products Other Zemaira HAEGARDA® +5% • KCENTRA® +18% Wound • New launches in EU and Australia − Exceeds pre-pandemic sales Healing exceeding expectations • RIASTAP® / Haegarda • Despite increased competition, HAEMOCOMPLETT
Slide 11: Plasma Collections
Plasma Collections For personal use only Growth Drivers Contemporary Topics • Operating and marketing • New COVID variants disruption to initiatives supporting donor operations recruitment and retention • Competitive US employment • Enhanced donor experience environment through increased use of • In
Slide 12: Plasma Collections
Plasma Collections Volume now exceeds pre-pandemic levels For personal use only 2020 2021 • Annual tax season drop 2022 • Pandemic and lockdowns begin • Vaccine momentum • Further initiatives Holiday • Stimulus burn-off Season Initiatives launched US fiscal stimulus JAN FEB MAR APR MAY JUN JULY AUG
Slide 13: CSL Behring: Well positioned for growth post COVID
CSL Behring Well positioned for growth post COVID For personal use only Investment In Ig Manufacturing Demand Collections Capacity • Collection centre fleet growth of • Ig yield improvement • Lead indicators of disease diagnosis >30% over COVID period initiatives returning • ~10% beds temporarily re
Slide 14: CSL Seqirus
CSL Seqirus1 Revenue up 13% For personal use only Revenue Change1 Revenue By Region1 Therapy $m % Egg Based 228 (25%) +16% Cell Culture 486 10% Seasonal 4% 7% Influenza Asia Adjuvanted Egg 885 41% vaccines Pacific 13% Other / In-licence 178 2% North US$2.0B America 57% Total Product Sales 1,777 15%
Slide 15: CSL Seqirus Operating Highlights
CSL Seqirus Operating Highlights For personal use only 135 million doses 65 + FLUAD ® years • Record volume distributed FY22 • CDC adopted ACIP’s recommendation to be a preferentially recommended seasonal vaccine option for adults aged 65+ years EU / UK US • Strong growth in differentiated • US seas
Slide 16: R&D Highlights, Partnerships & Alliances
R&D Highlights Partnerships & Alliances For personal use only Immunology Cardiovascular & Metabolic • CSL, WEHI, & University of Melbourne secured State Government funding to create biotech start-up incubator in • Garadacimab (Anti-FXIIa) HAE • CSL112 (ApoA-1) CSL’s new global headquarters under – P
Slide 17: Financials
For personal use only Financials Joy Linton CFO 16
Slide 18: Financial Highlights
Financial Highlights Net profit after tax For personal use only -5% $2,375m reported $2,255m FX$19m $2,236m -6% @CC1 • CSL has delivered in line with @CC1 expectations • Increased cost for collections • Higher fixed cost absorption on lower plasma volumes • Includes net contribution of ~$70m from: •
Slide 19: Financial Highlights: CSL Group
Financial Highlights CSL Group For personal use only FY21 FY22 FY22 Change 1 US$ Millions Reported Reported at CC % Total Revenue 10,310 10,562 10,668 3%1 Gross Profit 5,843 5,732 5,786 (1%)1 GP margin 56.7% 54.3% 54.2% EBIT 3,130 2,927 2,872 (8%)1 EBIT margin 30.4% 27.7% 26.9% NPAT 2,375 2,255 2,23
Slide 20: Financial Highlights: Segments
Financial Highlights Segments For personal use only CSL Behring CSL Seqirus FY21 FY22 Change FY21 FY22 Change 1 1 US$ Millions Reported Reported % at CC US$ Millions Reported Reported % at CC Sales 8,428 8,360 0% Sales 1,552 1,777 15% Other Revenue 146 238 63% Other Revenue 184 187 1% Total Revenue
Slide 21: Financial Highlights: Investing in R&D, Controlling SG&A
Financial Highlights Investing in R&D Reported Expenses Controlling SG&A costs For personal use only R&D 1 • Trials resumed post COVID pause Change @ CC FY22 • Within guidance of 10-11% of $m $m % revenue Research & Development 1,156 171 17% SG&A • Etranacogene dezaparvovec Sales & Marketing 961 0 0
Slide 22: Inventory
Inventory For personal use only $M Inventory $4,333m $3,781m 4,000 0% 3,000 Key Insights • FY22 reflects increased volumes +28% of plasma collected, as well as 2,000 increased cost per litre of plasma 1,000 • FY23 rebuilding finished goods +16% inventory, following depletion during COVID years 0 FY2
Slide 23: Debt Profile
Debt Profile For personal use only Wide range of maturities enhancing flexibility Key Insights US$m 11.8 years 1,600 Weighted average tenor 1,400 1,200 3.38% 1,000 Weighted average cost of debt 800 Credit ratings maintained 600 400 Moodys A3 S&P A- 200 - FY23 FY25 FY27 FY29 FY31 FY33 FY35 FY37 FY42
Slide 24: Sustainability Strategy
Sustainability Strategy Focused on 3 key pillars – For personal use only Environment, Social and Sustainable Workplace Carbon emissions reduction targets Scope 1 & 2 Scope 3 A reduction of 40% of absolute Scope 1 & 2 Ensure suppliers who contribute 67% of emissions against a baseline of the Scope 3
Slide 25: Outlook
Outlook1 Strong mid-term outlook as COVID recedes For personal use only Promising cluster of R&D programs nearing completion CSL Behring CSL Seqirus CSL Group • Strong plasma • Ongoing Northern • Continue to navigate collections and Ig Hemisphere challenging external growth anticipated demand for co
Slide 26: CSL Contacts
For personal use only CSL Contacts Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au Bernard Ronchi Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Investor Relations +61 3 9389 6798 stephen.mckeon@csl.com.au
Slide 27: Notes
Notes For personal use only (#) Constant currency removes the impact of Summary NPAT exchange rate movements to facilitate Reported net profit after tax $2,254.7m comparability of operational performance for the Currency effect $ (19.1m) Group. This is done in three parts: a) by converting Constant